| Asymmetric septal hypertrophy - a marker of hypertension in aortic stenosis (a SEAS substudy). | |
| | |
MedLine Citation:
|
PMID: 20429691 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Some patients with aortic stenosis develop asymmetric septal hypertrophy (ASH) that may influence the surgical approach and is associated with higher perioperative morbidity. The aim of this analysis was to characterize further this subtype of aortic stenosis patients. METHODS: Baseline data in 1719 patients with asymptomatic aortic stenosis, participating in the Simvastatin Ezetimibe in Aortic Stenosis study evaluating the effect of combined treatment with simvastatin and ezetimibe on progression of aortic stenosis was used. The study population was divided according to presence of ASH (interventricular septal/posterior wall thickness ratio >1.5). Left ventricular (LV) hypertrophy was considered present if LV mass index > or =104 g/m(2) in women and > or =116 g/m(2) in men. RESULTS: ASH was present in 22% of patients and associated with higher LV mass index, total peripheral resistance and peak transaortic velocity and concomitant hypertension (all p<0.05). Thirty-four percent of patients with ASH had combined ASH and LV hypertrophy (asymmetric LV hypertrophy). These patients had higher systolic blood pressure, lower LV ejection fraction and larger left atrial diameter than patients with ASH only. In logistic regression analyses, hypertension was the most important predictor both for ASH (odds ratio, OR 1.38 [1.05-1.82]) and for asymmetric LV hypertrophy (OR 2.99 [1.71-5.25]), both p<0.05) independent of other covariates including severity of aortic stenosis. CONCLUSION: Hypertension is the main clinic characteristic of ASH and asymmetric LV hypertrophy in patients with asymptomatic aortic stenosis independent of severity of aortic stenosis. |
| | |
Authors:
|
Nora Tuseth; Dana Cramariuc; Ashild E Rieck; Kristian Wachtell; Eva Gerdts |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Blood pressure Volume: 19 ISSN: 1651-1999 ISO Abbreviation: Blood Press. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-20 Completed Date: 2010-08-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9301454 Medline TA: Blood Press Country: England |
Other Details:
|
Languages: eng Pagination: 140-4 Citation Subset: IM |
Affiliation:
|
Department of Heart Disease, Haukeland University Hospital, Bergen, Norway. ntuseth@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aortic Valve Stenosis
/
complications*,
physiopathology* Azetidines Biological Markers Cardiomegaly / complications Cardiomyopathy, Hypertrophic / complications Female Heart Atria / physiopathology Humans Hypertension / complications Hypertrophy, Left Ventricular / complications, physiopathology Male Simvastatin |
| Chemical | |
Reg. No./Substance:
|
0/Azetidines; 0/Biological Markers; 163222-33-1/ezetimibe; 79902-63-9/Simvastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in tr...
Next Document: Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis.